SG11201811564QA - Methods of treating ovarian cancer - Google Patents
Methods of treating ovarian cancerInfo
- Publication number
- SG11201811564QA SG11201811564QA SG11201811564QA SG11201811564QA SG11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA SG 11201811564Q A SG11201811564Q A SG 11201811564QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- massachusetts
- tesaro
- waltham
- suite
- Prior art date
Links
- 206010033128 Ovarian cancer Diseases 0.000 title abstract 2
- 206010061535 Ovarian neoplasm Diseases 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000012661 PARP inhibitor Substances 0.000 abstract 1
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 abstract 1
- 208000000260 Warts Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 201000010153 skin papilloma Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662356461P | 2016-06-29 | 2016-06-29 | |
| US201662402427P | 2016-09-30 | 2016-09-30 | |
| US201762470141P | 2017-03-10 | 2017-03-10 | |
| PCT/US2017/040039 WO2018005818A1 (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201811564QA true SG11201811564QA (en) | 2019-01-30 |
Family
ID=60787744
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201811564QA SG11201811564QA (en) | 2016-06-29 | 2017-06-29 | Methods of treating ovarian cancer |
Country Status (23)
| Country | Link |
|---|---|
| US (5) | US20180311224A1 (fi) |
| EP (2) | EP3478286B1 (fi) |
| JP (2) | JP7083760B2 (fi) |
| KR (2) | KR102510996B1 (fi) |
| CN (1) | CN109640992A (fi) |
| AU (1) | AU2017290244B2 (fi) |
| BR (1) | BR112018077492A2 (fi) |
| CA (1) | CA3029671C (fi) |
| DK (1) | DK3478286T3 (fi) |
| ES (1) | ES2969816T3 (fi) |
| FI (1) | FI3478286T3 (fi) |
| HR (1) | HRP20240136T1 (fi) |
| HU (1) | HUE064978T2 (fi) |
| IL (1) | IL263925B2 (fi) |
| LT (1) | LT3478286T (fi) |
| MX (1) | MX2018016193A (fi) |
| NZ (1) | NZ749413A (fi) |
| PL (1) | PL3478286T3 (fi) |
| PT (1) | PT3478286T (fi) |
| RS (1) | RS65180B1 (fi) |
| SG (1) | SG11201811564QA (fi) |
| SI (1) | SI3478286T1 (fi) |
| WO (1) | WO2018005818A1 (fi) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201903867YA (en) | 2016-11-01 | 2019-05-30 | Anaptysbio Inc | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| US11155624B2 (en) | 2016-11-01 | 2021-10-26 | Anaptysbio, Inc. | Antibodies directed against programmed death-1 (PD-1) |
| KR102606252B1 (ko) | 2017-01-09 | 2023-11-23 | 테사로, 인코포레이티드 | 항-pd-1 항체로 암을 치료하는 방법 |
| CN110382000A (zh) | 2017-01-09 | 2019-10-25 | 泰萨罗公司 | 用抗tim-3抗体治疗癌症的方法 |
| MX2019011496A (es) | 2017-03-27 | 2020-01-23 | Tesaro Inc | Composiciones de niraparib. |
| EP3615513B1 (en) | 2017-04-24 | 2022-07-20 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| MA48637A (fr) * | 2017-05-09 | 2021-03-17 | Merck Sharp & Dohme | Polythérapies pour le traitement du cancer |
| CN110913911A (zh) | 2017-05-18 | 2020-03-24 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| AU2018341479B2 (en) | 2017-09-26 | 2022-02-17 | Tesaro, Inc. | Niraparib formulations |
| EP3697442A4 (en) | 2017-09-30 | 2021-07-07 | Tesaro, Inc. | COMBINATION THERAPIES FOR TREATMENT OF CANCER |
| CA3076859A1 (en) | 2017-10-06 | 2019-04-11 | Tesaro, Inc. | Combination therapies and uses thereof |
| WO2019152989A1 (en) * | 2018-02-05 | 2019-08-08 | Tesaro, Inc | Pediatric niraparib formulations and pediatric treatment methods |
| WO2019195443A1 (en) * | 2018-04-04 | 2019-10-10 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and a parp inhibitor |
| WO2020072797A1 (en) | 2018-10-03 | 2020-04-09 | Tesaro, Inc. | Niraparib salts |
| CN113330007A (zh) | 2018-10-03 | 2021-08-31 | 特沙诺有限公司 | 尼拉帕利游离碱的晶体形式 |
| US11640859B2 (en) | 2018-10-17 | 2023-05-02 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| US10395772B1 (en) | 2018-10-17 | 2019-08-27 | Tempus Labs | Mobile supplementation, extraction, and analysis of health records |
| JP2022516170A (ja) * | 2019-01-04 | 2022-02-24 | アクティニウム ファーマシューティカルズ インコーポレイテッド | Ｐａｒｐインヒビターおよび抗体放射性物質結合体の組み合わせを使用してがんを処置するための方法 |
| US11705226B2 (en) | 2019-09-19 | 2023-07-18 | Tempus Labs, Inc. | Data based cancer research and treatment systems and methods |
| TW202116316A (zh) * | 2019-07-15 | 2021-05-01 | 美商提薩羅有限公司 | 治療卵巢、輸卵管及腹膜癌之方法 |
| US11295841B2 (en) * | 2019-08-22 | 2022-04-05 | Tempus Labs, Inc. | Unsupervised learning and prediction of lines of therapy from high-dimensional longitudinal medications data |
| JP2023548110A (ja) * | 2020-10-29 | 2023-11-15 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 卵巣がんの検出及び治療方法 |
| KR20230114557A (ko) | 2022-01-25 | 2023-08-01 | 서울대학교산학협력단 | 상동 재조합 결핍 연관 유전자 도출 장치 및 방법, 상동 재조합 결핍 판단 모델 생성 장치 및 방법과, 상동 재조합 결핍 판단 장치 및 방법 |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
| CN115253066A (zh) * | 2022-07-21 | 2022-11-01 | 湖南安泰康成生物科技有限公司 | 卵巢癌治疗系统以及卵巢癌治疗的交变电场发生装置 |
| CN116092631A (zh) * | 2023-01-17 | 2023-05-09 | 湖南安泰康成生物科技有限公司 | 铁死亡诱导剂与电场联用的肿瘤治疗系统 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2109608T3 (pl) | 2007-01-10 | 2011-08-31 | Msd Italia Srl | Indazole podstawione grupą amidową jako inhibitory polimerazy poli(ADP-rybozy)-(PARP) |
| CN101918003A (zh) * | 2007-11-12 | 2010-12-15 | 彼帕科学公司 | 单独使用parp抑制剂或与抗肿瘤剂组合治疗子宫癌和卵巢癌 |
| NZ586675A (en) | 2008-01-08 | 2012-04-27 | Merck Sharp & Dohme | Pharmaceutically acceptable salts of 2-{ 4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| ES2609931T3 (es) | 2010-06-18 | 2017-04-25 | Myriad Genetics, Inc. | Métodos y materiales para evaluar la pérdida de heterocigosidad |
| DK3109325T3 (en) | 2010-08-24 | 2019-01-28 | Dana Farber Cancer Inst Inc | Methods for predicting anticancer response |
| WO2014052550A1 (en) * | 2012-09-27 | 2014-04-03 | Thomas Jefferson University | Use of parp inhibitors to treat breast cancer |
| WO2014165785A2 (en) * | 2013-04-05 | 2014-10-09 | Myriad Genetics, Inc. | Methods and materials for assessing homologous recombination deficiency |
| CN105917007A (zh) * | 2014-01-16 | 2016-08-31 | 克洛维斯肿瘤有限公司 | Parp抑制剂用以治疗显示杂合性丧失的乳腺癌或卵巢癌患者的用途 |
| EP3148336B1 (en) * | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| US20150344968A1 (en) * | 2014-05-30 | 2015-12-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Methods for determining parp inhibitor and platinum resistance in cancer therapy |
| CN105384695B (zh) * | 2014-08-22 | 2019-12-20 | 四川海思科制药有限公司 | 嘧啶衍生物及其制备方法和在医药上的应用 |
| WO2017151554A1 (en) * | 2016-02-29 | 2017-09-08 | Synta Pharmaceuticals Corp | Combination therapy for treatment of ovarian cancer |
-
2017
- 2017-06-29 KR KR1020197002633A patent/KR102510996B1/ko active IP Right Grant
- 2017-06-29 EP EP17821262.7A patent/EP3478286B1/en active Active
- 2017-06-29 SI SI201731481T patent/SI3478286T1/sl unknown
- 2017-06-29 MX MX2018016193A patent/MX2018016193A/es unknown
- 2017-06-29 JP JP2018568951A patent/JP7083760B2/ja active Active
- 2017-06-29 WO PCT/US2017/040039 patent/WO2018005818A1/en active Application Filing
- 2017-06-29 AU AU2017290244A patent/AU2017290244B2/en active Active
- 2017-06-29 BR BR112018077492-8A patent/BR112018077492A2/pt unknown
- 2017-06-29 PT PT178212627T patent/PT3478286T/pt unknown
- 2017-06-29 HU HUE17821262A patent/HUE064978T2/hu unknown
- 2017-06-29 LT LTEPPCT/US2017/040039T patent/LT3478286T/lt unknown
- 2017-06-29 PL PL17821262.7T patent/PL3478286T3/pl unknown
- 2017-06-29 RS RS20240163A patent/RS65180B1/sr unknown
- 2017-06-29 KR KR1020237008762A patent/KR20230042136A/ko not_active Application Discontinuation
- 2017-06-29 IL IL263925A patent/IL263925B2/en unknown
- 2017-06-29 FI FIEP17821262.7T patent/FI3478286T3/fi active
- 2017-06-29 CA CA3029671A patent/CA3029671C/en active Active
- 2017-06-29 ES ES17821262T patent/ES2969816T3/es active Active
- 2017-06-29 EP EP23211450.4A patent/EP4302835A3/en active Pending
- 2017-06-29 HR HRP20240136TT patent/HRP20240136T1/hr unknown
- 2017-06-29 NZ NZ749413A patent/NZ749413A/en unknown
- 2017-06-29 SG SG11201811564QA patent/SG11201811564QA/en unknown
- 2017-06-29 CN CN201780051916.1A patent/CN109640992A/zh active Pending
- 2017-06-29 DK DK17821262.7T patent/DK3478286T3/da active
-
2018
- 2018-05-22 US US15/986,536 patent/US20180311224A1/en active Granted
-
2021
- 2021-12-27 JP JP2021212103A patent/JP2022031478A/ja active Pending
-
2022
- 2022-02-24 US US17/652,457 patent/US20220395493A1/en not_active Abandoned
- 2022-02-24 US US17/652,422 patent/US20220175751A1/en not_active Abandoned
- 2022-02-24 US US17/652,443 patent/US20220175752A1/en not_active Abandoned
-
2023
- 2023-09-08 US US18/463,851 patent/US20240058319A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201909955XA (en) | Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201906192SA (en) | Methods of treating cancer with anti-pd-1 antibodies | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
| SG11201908465QA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
| SG11201809561WA (en) | 9-aminomethyl minocycline compounds and methods of use thereof in urinary tract infection (uti) treatment | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901925RA (en) | Methods of treating acute kidney injury | |
| SG11201900123TA (en) | Compositions and methods for treating frontotemporal dementia | |
| SG11201903842YA (en) | Combination treatment with antibody-drug conjugates and parp inhibitors | |
| SG11201903236SA (en) | Lasofoxifene treatment of er+ breast cancer | |
| SG11201908998XA (en) | Compositions and methods for detecting and treating prostate cancer using progastrin binding molecule |